Showing 5401-5410 of 5643 results for "".
- MDI Biological Laboratory Scientist Receives Scientific Innovation Award for Research on AMDhttps://modernod.com/news/mdi-biological-laboratory-scientist-receives-scientific-innovation-award-for-research-on-amd/2476162/Vicki P. Losick, PhD, has been named the inaugural recipient of an award from the William Procter Scientific Innovation Fund. The award will support her research at the MDI Biological Laboratory on age-related macular degeneration (AMD). The Procter Fund was established at the MDI Biologic
- EyeCare Partners Acquires Holcomb Laser Centerhttps://modernod.com/news/eyecare-partners-acquires-holcomb-laser-center/2479632/EyeCare Partners (ECP) furthered its expansion into the Alabama ophthalmology market with the acquisition of Dr. William Holcomb’s Cullman, Alabama-based Holcomb Laser Center, according to an announcement from EyeCare Partners, as reported in VisionMonday. Terms of the deal were not disclo
- Alcon Outlines Growth Strategy as Spinoff Nearshttps://modernod.com/news/alcon-outlines-growth-strategy-as-spinoff-nears/2479633/With its proposed spinoff from Novartis just months away, Alcon executives said they will focus on an aging population and the myopia epidemic to drive growth. Alcon executives
- Dry Eye Symptom Screens Show Modest Accuracyhttps://modernod.com/news/dry-eye-symptom-screens-show-modest-accuracy/2479636/In head-to-head comparisons, two of five dry eye screens showed a statistically significant ability to detect signs of the disorder, but all demonstrated relatively modest diagnostic accuracy, researchers say, according to a Reuters report
- Glaucoma-Staging Systems May Underestimate Severityhttps://modernod.com/news/glaucoma-staging-systems-may-underestimate-severity/2479639/Standard automated perimetry (SAP) testing is often used to classify glaucoma severity but may fail to detect macular damage, according to New York City-based researchers, as reported in Reuters. “Because current staging syst
- New Data Indicate that EyeMax Mono Offers Significant Improvement in Visual Function in Dry AMD Patientshttps://modernod.com/news/new-data-indicate-that-eyemax-mono-offers-significant-improvement-in-visual-function-in-dry-amd-patients/2479640/LEH Pharma announced new data published in the Journal of Refractive Surgery, suggesting that EyeMax Mono offers benefits in terms of visual function for people with dry age-related macular degeneration (AMD). EyeMax Mono is an IOL specifically designed to deliver improved visual outcome
- Genentech Acquires Jecure Therapeuticshttps://modernod.com/news/genentech-acquires-jecure-therapeutics/2479641/Jecure Therapeutics, a biotechnology company with drug discovery programs targeting serious inflammatory diseases, announced a definitive agreement by which it will be acquired by Genentech, the maker of Lucentis (ranibizumab). Terms of the deal were not disclosed. With this acquis
- Interface Biologics Completes Pre-IND Meeting with FDA on Epidel Technology for Treatment of Posterior Inflammatory Eye Diseaseshttps://modernod.com/news/interface-biologics-completes-pre-ind-meeting-with-fda-on-epidel-technology-for-treatment-of-posterior-inflammatory-eye-diseases/2479645/Interface Biologics has announced a positive pre-investigational new drug meeting with the FDA for its dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases. The FDA concurred with IBI’s manufacturing and clinical development plans, based on the precl
- AcuFocus Receives IDE Approval from the FDA to Begin Clinical Study of the IC-8 Lenshttps://modernod.com/news/acufocus-receives-ide-approval-from-the-fda-to-begin-clinical-study-of-the-ic-8-lens/2479646/AcuFocus announced that it has received approval for an investigational device exemption (IDE) from the FDA to conduct a pivotal study of the company’s IC-8 small aperture IOL for patients with cataracts. The AcuFocus IC-8 IOL is a clear monofocal lens with an embedded mini-ring or pinhole
- Gene Therapy Luxturna Approved in EU to Restore Vision in People With Rare Inherited Retinal Diseasehttps://modernod.com/news/gene-therapy-luxturna-approved-in-eu-to-restore-vision-in-people-with-rare-inherited-retinal-disease/2479651/Novartis announced that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells. The authorization is valid in all 28 member st